Skip to main content
. Author manuscript; available in PMC: 2018 Aug 28.
Published in final edited form as: Expert Rev Vaccines. 2017 Sep 25;16(12):1253–1266. doi: 10.1080/14760584.2017.1383159

Figure 1.

Figure 1.

FDA-Approved Biologicals. (a) The accumulation of innovative passive (grey) and active (red) immune-based therapies is shown over time. (b) The accumulation of innovative passive and active immune product that were available for use in the United States as of the end of 2015 are shown.